,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2017', 'fs': 'Nov 2017', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAE2A3'}, 'Id': 'a0POZ00000R5FAE2A3', 'Event_Date__c': '2017-11-10', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Nov 2017', 'Status_History__c': 'a132P000000ArMnQAK'}, 'change': None}, {'Summary': {'s': 'Consumer application received.', 'fs': 'Consumer application received.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2025', 'fs': 'Apr 2025', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAQ2A3'}, 'Id': 'a0POZ00000R5FAQ2A3', 'Event_Date__c': '2025-04-23', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'Consumer application received.', 'Formatted_Date__c': 'Apr 2025', 'Status_History__c': 'a13OZ00000N1ELSYA3'}, 'change': None}]",Nov 2017,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The Subcommittee recommended that the application for the funding of pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or high-risk early stage breast cancer be declined based on insufficient evidence available at this time.', 'fs': 'The Subcommittee recommended that the application for the funding of pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or high-risk early stage breast cancer be declined based on insufficient evidence available at this time.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2018-09.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2018-09.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 21 September 2018.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 21 September 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAF2A3'}, 'Id': 'a0POZ00000R5FAF2A3', 'Event_Date__c': '2018-09-21', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 21 September 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2018-09.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Subcommittee recommended that the application for the funding of pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or high-risk early stage breast cancer be declined based on insufficient evidence available at this time.', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArXXQA0'}, 'change': None}, {'Summary': {'s': 'PTAC accepted the Subcommittee&#39;s recommendation.', 'fs': 'PTAC accepted the Subcommittee&#39;s recommendation.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAG2A3'}, 'Id': 'a0POZ00000R5FAG2A3', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'PTAC accepted the Subcommittee&#39;s recommendation.', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000ArarQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee <strong>recommended</strong> that pertuzumab be listed with a <strong>medium priority</strong>, in the context of treatments for malignant disease, subject to the following Special Authority criteria:</p><p class=""ql-indent-1"" style=""text-align: justify;""><strong style=""font-family: sans-serif; font-size: 10px;"">I</strong><strong style=""font-family: sans-serif; font-size: 11px;"">nitial application – (breast cancer, neoadjuvant) </strong><span style=""font-family: sans-serif; font-size: 11px;"">only from a relevant specialist or any other practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">All of the following:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">1.\xa0\xa0\xa0\xa0The patient has breast cancer expressing HER2 IHC3+ or ISH+ (including FISH or other technology); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">2.\xa0\xa0\xa0\xa0The patient’s condition is treatment naïve; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">3.\xa0\xa0\xa0\xa0Both:</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">3.1.\xa0\xa0The patient has locally advanced or inflammatory breast cancer; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">3.2.\xa0\xa0The patient has high risk early-stage breast cancer (either greater than 2 cm in diameter or node positive); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">4.\xa0\xa0\xa0\xa0Pertuzumab to be administered for a maximum of 4 cycles.</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation the Committee considered the following:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>health need of people with HER-2 positive breast cancer, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>breast cancer (including HER-2 positive) is an area of Māori health focus, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>health benefit demonstrated by pathological complete response (pCR), and the health benefit associated with earlier treatment in many oncology indications, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>reduced use of adjuvant therapy providing potential savings for the health system, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>neoadjuvant treatment being more suitable than adjuvant treatment.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee <strong>recommended</strong> that pertuzumab be listed with a <strong>medium priority</strong>, in the context of treatments for malignant disease, subject to the following Special Authority criteria:</p><p class=""ql-indent-1"" style=""text-align: justify;""><strong style=""font-family: sans-serif; font-size: 10px;"">I</strong><strong style=""font-family: sans-serif; font-size: 11px;"">nitial application – (breast cancer, neoadjuvant) </strong><span style=""font-family: sans-serif; font-size: 11px;"">only from a relevant specialist or any other practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">All of the following:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">1.\xa0\xa0\xa0\xa0The patient has breast cancer expressing HER2 IHC3+ or ISH+ (including FISH or other technology); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">2.\xa0\xa0\xa0\xa0The patient’s condition is treatment naïve; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">3.\xa0\xa0\xa0\xa0Both:</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">3.1.\xa0\xa0The patient has locally advanced or inflammatory breast cancer; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">3.2.\xa0\xa0The patient has high risk early-stage breast cancer (either greater than 2 cm in diameter or node positive); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">4.\xa0\xa0\xa0\xa0Pertuzumab to be administered for a maximum of 4 cycles.</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation the Committee considered the following:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>health need of people with HER-2 positive breast cancer, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>breast cancer (including HER-2 positive) is an area of Māori health focus, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>health benefit demonstrated by pathological complete response (pCR), and the health benefit associated with earlier treatment in many oncology indications, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>reduced use of adjuvant therapy providing potential savings for the health system, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>neoadjuvant treatment being more suitable than adjuvant treatment.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that an application for pertuzumab for neoadjuvant treatment for HER2+ve, locally advanced, inflammatory or early-stage breast cancer was assessed by the Committee at their <a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2018-09.pdf"" target=""_blank"">September 2018 meeting</a>. The Committee had recommended this application be declined based on insufficient evidence and considered that any reconsideration would require additional evidence powered to detect a progression free survival (PFS) and overall survival (OS) benefit. </p><p><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the first trials (<a href=""https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext"" target=""_blank"">Gianni L, et al. Lancet Oncol. 2012;13(1):25-32</a> and <a href=""https://www.annalsofoncology.org/article/S0923-7534(19)36929-7/fulltext"" target=""_blank"">Schneeweiss A, et al. Ann Oncol. 2013;24(9):2278-84</a>) were in large heterogenous populations with high response rates but no clear survival benefit. The Committee considered that there was now supporting data that there was high pCR (pathological complete response) in certain phenotypes including HER2+ at 39-60%, which may correlate with a survival advantage. </p><p><br></p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted a meta-analysis which reported that pCR was associated with improved event free survival and overall survival (OS) compared to non-pCR (<a href=""https://jamanetwork.com/journals/jamaoncology/article-abstract/2492724"" target=""_blank"">Broglio et al. JAMA Oncol. 2016;2: 751-760</a>). The Committee considered that the magnitudes of the associations between pCR and these final clinical endpoints were uncertain, limiting the ability to predict the absolute overall survival of pertuzumab in the neoadjuvant setting. The Committee noted however that in other jurisdictions, pCR was accepted as a surrogate marker for OS. </p><p><br></p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered correspondence from the supplier (Roche) with further evidence to support its initial application. The Committee considered the 5-year follow up from the initial NeoSphere trial (<a href=""https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00163-7/fulltext"" target=""_blank"">Gianni L, et al. Lancet Oncol. 2016;17(6):791-800</a>) and PEONY trial (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813591/"" target=""_blank"">Shao Z, et al. JAMA Oncol. 2020;6(3):e193692</a>). The Committee considered the additional follow up from the NeoSphere trial had small participant numbers and noted the confidence interval of the relative PFS in treatment compared to non-treatment overlapped. The Committee considered that the assessment of the impact of pertuzumab on PFS was not strong based on this evidence. The Committee noted the PEONY study comparing those treated with docetaxel and trastuzumab alone with those treated with docetaxel, trastuzumab and pertuzumab in the neoadjuvant setting. The Committee noted that the trial reported a higher objective response rate (78% v 88%) and higher statistically significant pCR in the pertuzumab arm of the trial. The Committee noted that no OS or PFS data was reported in the paper. The Committee considered these outcomes were similar to the initial NeoSphere trial assessed in 2018. The Committee considered the low score from European Society for Medical Oncology (ESMO) clinical benefit scale, but noted the PEONY trial was not considered in this score. </p><p><br></p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted seven other studies submitted by the supplier and considered they were not relevant to the application, as they contained pertuzumab in all trial arms and therefore did not provide evidence of the incremental benefit associated with pertuzumab. The Committee noted that generally, the earlier treatment was more beneficial in oncology indications. The Committee noted that an increasing proportion of trials of neoadjuvant therapies for HER2+ breast cancer contained pertuzumab as part of their backbone, and this reflected use of pertuzumab as standard of care in the neoadjuvant setting in other jurisdictions. The Committee considered given the use of neoadjuvant pertuzumab as standard of care in many other countries, that it was unlikely additional evidence would become available for this indication. </p><p><br></p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for pertuzumab if it were to be funded in New Zealand for neoadjuvant treatment of HER2+ breast cancer. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0</p><p><br></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000R5FAL&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002lD5J"" alt=""image.png""></img></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that an application for pertuzumab for neoadjuvant treatment for HER2+ve, locally advanced, inflammatory or early-stage breast cancer was assessed by the Committee at their <a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2018-09.pdf"" target=""_blank"">September 2018 meeting</a>. The Committee had recommended this application be declined based on insufficient evidence and considered that any reconsideration would require additional evidence powered to detect a progression free survival (PFS) and overall survival (OS) benefit. </p><p><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the first trials (<a href=""https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext"" target=""_blank"">Gianni L, et al. Lancet Oncol. 2012;13(1):25-32</a> and <a href=""https://www.annalsofoncology.org/article/S0923-7534(19)36929-7/fulltext"" target=""_blank"">Schneeweiss A, et al. Ann Oncol. 2013;24(9):2278-84</a>) were in large heterogenous populations with high response rates but no clear survival benefit. The Committee considered that there was now supporting data that there was high pCR (pathological complete response) in certain phenotypes including HER2+ at 39-60%, which may correlate with a survival advantage. </p><p><br></p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted a meta-analysis which reported that pCR was associated with improved event free survival and overall survival (OS) compared to non-pCR (<a href=""https://jamanetwork.com/journals/jamaoncology/article-abstract/2492724"" target=""_blank"">Broglio et al. JAMA Oncol. 2016;2: 751-760</a>). The Committee considered that the magnitudes of the associations between pCR and these final clinical endpoints were uncertain, limiting the ability to predict the absolute overall survival of pertuzumab in the neoadjuvant setting. The Committee noted however that in other jurisdictions, pCR was accepted as a surrogate marker for OS. </p><p><br></p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered correspondence from the supplier (Roche) with further evidence to support its initial application. The Committee considered the 5-year follow up from the initial NeoSphere trial (<a href=""https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00163-7/fulltext"" target=""_blank"">Gianni L, et al. Lancet Oncol. 2016;17(6):791-800</a>) and PEONY trial (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813591/"" target=""_blank"">Shao Z, et al. JAMA Oncol. 2020;6(3):e193692</a>). The Committee considered the additional follow up from the NeoSphere trial had small participant numbers and noted the confidence interval of the relative PFS in treatment compared to non-treatment overlapped. The Committee considered that the assessment of the impact of pertuzumab on PFS was not strong based on this evidence. The Committee noted the PEONY study comparing those treated with docetaxel and trastuzumab alone with those treated with docetaxel, trastuzumab and pertuzumab in the neoadjuvant setting. The Committee noted that the trial reported a higher objective response rate (78% v 88%) and higher statistically significant pCR in the pertuzumab arm of the trial. The Committee noted that no OS or PFS data was reported in the paper. The Committee considered these outcomes were similar to the initial NeoSphere trial assessed in 2018. The Committee considered the low score from European Society for Medical Oncology (ESMO) clinical benefit scale, but noted the PEONY trial was not considered in this score. </p><p><br></p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted seven other studies submitted by the supplier and considered they were not relevant to the application, as they contained pertuzumab in all trial arms and therefore did not provide evidence of the incremental benefit associated with pertuzumab. The Committee noted that generally, the earlier treatment was more beneficial in oncology indications. The Committee noted that an increasing proportion of trials of neoadjuvant therapies for HER2+ breast cancer contained pertuzumab as part of their backbone, and this reflected use of pertuzumab as standard of care in the neoadjuvant setting in other jurisdictions. The Committee considered given the use of neoadjuvant pertuzumab as standard of care in many other countries, that it was unlikely additional evidence would become available for this indication. </p><p><br></p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for pertuzumab if it were to be funded in New Zealand for neoadjuvant treatment of HER2+ breast cancer. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0</p><p><br></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000R5FAL&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002lD5J"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 28 October 2022.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 28 October 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAL2A3'}, 'Id': 'a0POZ00000R5FAL2A3', 'Event_Date__c': '2022-10-28', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 28 October 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Oct 2022', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee <strong>recommended</strong> that pertuzumab be listed with a <strong>medium priority</strong>, in the context of treatments for malignant disease, subject to the following Special Authority criteria:</p><p class=""ql-indent-1"" style=""text-align: justify;""><strong style=""font-family: sans-serif; font-size: 10px;"">I</strong><strong style=""font-family: sans-serif; font-size: 11px;"">nitial application – (breast cancer, neoadjuvant) </strong><span style=""font-family: sans-serif; font-size: 11px;"">only from a relevant specialist or any other practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">All of the following:</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">1.\xa0\xa0\xa0\xa0The patient has breast cancer expressing HER2 IHC3+ or ISH+ (including FISH or other technology); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">2.\xa0\xa0\xa0\xa0The patient’s condition is treatment naïve; and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">3.\xa0\xa0\xa0\xa0Both:</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">3.1.\xa0\xa0The patient has locally advanced or inflammatory breast cancer; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">3.2.\xa0\xa0The patient has high risk early-stage breast cancer (either greater than 2 cm in diameter or node positive); and</span></p><p class=""ql-indent-1"" style=""text-align: justify;""><span style=""font-family: sans-serif; font-size: 11px;"">4.\xa0\xa0\xa0\xa0Pertuzumab to be administered for a maximum of 4 cycles.</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation the Committee considered the following:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>health need of people with HER-2 positive breast cancer, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>breast cancer (including HER-2 positive) is an area of Māori health focus, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>health benefit demonstrated by pathological complete response (pCR), and the health benefit associated with earlier treatment in many oncology indications, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>reduced use of adjuvant therapy providing potential savings for the health system, and</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>neoadjuvant treatment being more suitable than adjuvant treatment.</p>', 'Published_Discussion__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that an application for pertuzumab for neoadjuvant treatment for HER2+ve, locally advanced, inflammatory or early-stage breast cancer was assessed by the Committee at their <a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2018-09.pdf"" target=""_blank"">September 2018 meeting</a>. The Committee had recommended this application be declined based on insufficient evidence and considered that any reconsideration would require additional evidence powered to detect a progression free survival (PFS) and overall survival (OS) benefit. </p><p><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the first trials (<a href=""https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext"" target=""_blank"">Gianni L, et al. Lancet Oncol. 2012;13(1):25-32</a> and <a href=""https://www.annalsofoncology.org/article/S0923-7534(19)36929-7/fulltext"" target=""_blank"">Schneeweiss A, et al. Ann Oncol. 2013;24(9):2278-84</a>) were in large heterogenous populations with high response rates but no clear survival benefit. The Committee considered that there was now supporting data that there was high pCR (pathological complete response) in certain phenotypes including HER2+ at 39-60%, which may correlate with a survival advantage. </p><p><br></p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted a meta-analysis which reported that pCR was associated with improved event free survival and overall survival (OS) compared to non-pCR (<a href=""https://jamanetwork.com/journals/jamaoncology/article-abstract/2492724"" target=""_blank"">Broglio et al. JAMA Oncol. 2016;2: 751-760</a>). The Committee considered that the magnitudes of the associations between pCR and these final clinical endpoints were uncertain, limiting the ability to predict the absolute overall survival of pertuzumab in the neoadjuvant setting. The Committee noted however that in other jurisdictions, pCR was accepted as a surrogate marker for OS. </p><p><br></p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered correspondence from the supplier (Roche) with further evidence to support its initial application. The Committee considered the 5-year follow up from the initial NeoSphere trial (<a href=""https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00163-7/fulltext"" target=""_blank"">Gianni L, et al. Lancet Oncol. 2016;17(6):791-800</a>) and PEONY trial (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813591/"" target=""_blank"">Shao Z, et al. JAMA Oncol. 2020;6(3):e193692</a>). The Committee considered the additional follow up from the NeoSphere trial had small participant numbers and noted the confidence interval of the relative PFS in treatment compared to non-treatment overlapped. The Committee considered that the assessment of the impact of pertuzumab on PFS was not strong based on this evidence. The Committee noted the PEONY study comparing those treated with docetaxel and trastuzumab alone with those treated with docetaxel, trastuzumab and pertuzumab in the neoadjuvant setting. The Committee noted that the trial reported a higher objective response rate (78% v 88%) and higher statistically significant pCR in the pertuzumab arm of the trial. The Committee noted that no OS or PFS data was reported in the paper. The Committee considered these outcomes were similar to the initial NeoSphere trial assessed in 2018. The Committee considered the low score from European Society for Medical Oncology (ESMO) clinical benefit scale, but noted the PEONY trial was not considered in this score. </p><p><br></p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted seven other studies submitted by the supplier and considered they were not relevant to the application, as they contained pertuzumab in all trial arms and therefore did not provide evidence of the incremental benefit associated with pertuzumab. The Committee noted that generally, the earlier treatment was more beneficial in oncology indications. The Committee noted that an increasing proportion of trials of neoadjuvant therapies for HER2+ breast cancer contained pertuzumab as part of their backbone, and this reflected use of pertuzumab as standard of care in the neoadjuvant setting in other jurisdictions. The Committee considered given the use of neoadjuvant pertuzumab as standard of care in many other countries, that it was unlikely additional evidence would become available for this indication. </p><p><br></p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for pertuzumab if it were to be funded in New Zealand for neoadjuvant treatment of HER2+ breast cancer. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0</p><p><br></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000R5FAL&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002lD5J"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000EDzYQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2023-07-21-Cancer-Treatments-Advisory-Committee-Record-Web-version.pdf"" target=""_blank"">Meeting record</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2023-07-21-Cancer-Treatments-Advisory-Committee-Record-Web-version.pdf"" target=""_blank"">Meeting record</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 21 July 2023.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 21 July 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAM2A3'}, 'Id': 'a0POZ00000R5FAM2A3', 'Event_Date__c': '2023-07-21', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 21 July 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2023-07-21-Cancer-Treatments-Advisory-Committee-Record-Web-version.pdf"" target=""_blank"">Meeting record</a></p>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a13OZ000006rQ49YAE'}, 'change': None}]",Sep 2018,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAH2A3'}, 'Id': 'a0POZ00000R5FAH2A3', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000ArbGQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2024', 'fs': 'May 2024', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAN2A3'}, 'Id': 'a0POZ00000R5FAN2A3', 'Event_Date__c': '2024-05-06', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2024', 'Status_History__c': 'a13OZ000009h8ehYAA'}, 'change': None}]",Feb 2019,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2020', 'fs': 'Jan 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAI2A3'}, 'Id': 'a0POZ00000R5FAI2A3', 'Event_Date__c': '2020-01-24', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jan 2020', 'Status_History__c': 'a132P000000BPsyQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2024', 'fs': 'Jun 2024', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAO2A3'}, 'Id': 'a0POZ00000R5FAO2A3', 'Event_Date__c': '2024-06-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2024', 'Status_History__c': 'a13OZ00000ArK4hYAF'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2025', 'fs': 'Mar 2025', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAP2A3'}, 'Id': 'a0POZ00000R5FAP2A3', 'Event_Date__c': '2025-03-18', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2025', 'Status_History__c': 'a13OZ00000LGQdfYAH'}, 'change': None}]",Jan 2020,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><span style=""font-size: 10pt; color: rgb(46, 75, 89);"">\xa0</span><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'fs': '<p><span style=""font-size: 10pt; color: rgb(46, 75, 89);"">\xa0</span><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAJ2A3'}, 'Id': 'a0POZ00000R5FAJ2A3', 'Event_Date__c': '2021-06-28', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><span style=""font-size: 10pt; color: rgb(46, 75, 89);"">\xa0</span><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CxfJQAS'}, 'change': None}]",Jun 2021,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Consultation outcome notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Consultation outcome notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2021', 'fs': 'Aug 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000R5FAK2A3'}, 'Id': 'a0POZ00000R5FAK2A3', 'Event_Date__c': '2021-08-02', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Consultation outcome notification</a></p>', 'Formatted_Date__c': 'Aug 2021', 'Status_History__c': 'a132P000000D3v7QAC'}, 'change': None}]",Aug 2021,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
